frontiers in Genetics

TYPE Correction
PUBLISHED 11 March 2026
DOI 10.3389/fgene.2026.1749292

Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY
Gary S. Stein,
University of Vermont, United States

*CORRESPONDENCE
Tianyou Chen,
dr_chentianyou@163.com
Yong Wang,
drwangyong_efy@163.com

RECEIVED 18 November 2025
REVISED 29 January 2026
ACCEPTED 04 March 2026
PUBLISHED 11 March 2026

CITATION
Wang L, Wang G, Song J, Yao D, Wang Y and Chen T (2026) Correction: A comprehensive analysis of the prognostic characteristics of microRNAs in breast cancer.
Front. Genet. 17:1749292.
doi: 10.3389/fgene.2026.1749292

COPYRIGHT
© 2026 Wang, Wang, Song, Yao, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: A comprehensive analysis of the prognostic characteristics of microRNAs in breast cancer

Lingying Wang[1], Gui Wang[2], Jiahong Song[2], Di Yao[1], Yong Wang[2]* and Tianyou Chen[1]*

[1]Department of Thoracic Surgery, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China, [2]Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

KEYWORDS
breast cancer, overall survival, disease specific survival, microRNA-551b, cancer progression

A Correction on
A comprehensive analysis of the prognostic characteristics of microRNAs in breast cancer

by Wang L, Wang G, Song J, Yao D, Wang Y and Chen T (2024). Front. Genet. 15:1293824. doi: 10.3389/fgene.2024.1293824

There was a mistake in Figure 6 as published. The authors misused the images of NC, antagomiR-551b and agomiR-551b in Figure 6D. The corrected Figure 6 appears below.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



FIGURE 6
Effects of miR-551b on the proliferation, invasion, and migration of breast cancer (BC). **(A,B)** miR-551b was relatively low expressed in breast cancer tissues and cells; **(C)** CCK8 experiments showed that cell proliferation was significantly enhanced or inhibited at 48 and 72 h after interfering or overexpressing miR-551b in MDA-MB-231 cells, respectively; **(D,E)** Transwell experiments showed that the interference or overexpression of miR-551b invasive ability of MDA-MB-231 cells was significantly enhanced or inhibited; **(F,G)** Scratch assay showed that the migration ability of breast cancer cells was significantly enhanced or inhibited after interfering or overexpressing miR-551b in MDA-MB-231.